Interaction Between Non-Coding RNAs and Androgen Receptor with an Especial Focus on Prostate Cancer
Overview
Biophysics
Cell Biology
Molecular Biology
Authors
Affiliations
The androgen receptor (AR) is a member of the nuclear receptor superfamily and has three functional domains, namely the N-terminal, DNA binding, and C-terminal domain. The N-terminal domain harbors potent transactivation functions, whereas the C-terminal domain binds to androgens and antiandrogens used to treat prostate cancer. AR has genomic activity being DNA binding-dependent or through interaction with other DNA-bound transcription factors, as well as a number of non-genomic, non-canonical functions, such as the activation of the ERK, AKT, and MAPK pathways. A bulk of evidence indicates that non-coding RNAs have functional interactions with AR. This type of interaction is implicated in the pathogenesis of human malignancies, particularly prostate cancer. In the current review, we summarize the available data on the role of microRNAs, long non-coding RNAs, and circular RNAs on the expression of AR and modulation of AR signaling, as well as the effects of AR on their expression. Recognition of the complicated interaction between non-coding RNAs and AR has practical importance in the design of novel treatment options, as well as modulation of response to conventional therapeutics.
A novel lncRNA FLJ promotes castration resistance in prostate cancer through AR mediated autophagy.
Wu Y, Cheng S, Zhang T, Wang L, Li T, Zheng Y J Transl Med. 2025; 23(1):255.
PMID: 40033417 PMC: 11874752. DOI: 10.1186/s12967-025-06294-9.
Editorial: Epigenetics in prostate cancer.
Baniahmad A, Ozen M Front Oncol. 2023; 13:1268519.
PMID: 38023204 PMC: 10661226. DOI: 10.3389/fonc.2023.1268519.
Circular RNA as a Novel Regulator and Promising Biomarker in Polycystic Ovary Syndrome.
Jing T, Wu Y, Wan A, Ge C, Chen Z, Du Y Biomolecules. 2023; 13(7).
PMID: 37509138 PMC: 10377156. DOI: 10.3390/biom13071101.
Importance of long non-coding RNAs in the pathogenesis, diagnosis, and treatment of prostate cancer.
Taheri M, Badrlou E, Hussen B, Kashi A, Ghafouri-Fard S, Baniahmad A Front Oncol. 2023; 13:1123101.
PMID: 37025585 PMC: 10070735. DOI: 10.3389/fonc.2023.1123101.
Stevens C, Hightower A, Buxbaum S, Falzarano S, Rhie S Front Oncol. 2023; 13:1079037.
PMID: 36937425 PMC: 10018228. DOI: 10.3389/fonc.2023.1079037.